title: CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
abstract: CD73 is a cell-surface enzyme that suppresses immune responses by producing extracellular adenosine. In this study, we employed CD73 gene-targeted mice to investigate the role of host-derived CD73 on antitumor immunity and tumor cell metastasis. We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma. The protective effect of CD73 deficiency on primary tumors was dependent on CD8(+) T cells and associated with an increased frequency of antigen-specific CD8(+) T cells in peripheral blood and tumors and increased antigen-specific IFN-γ production. Replicate studies in bone marrow chimeras established that both hematopoietic and nonhematopoietic expression of CD73 was important to promote tumor immune escape. Using adoptive reconstitution of T regulatory cell (Treg)-depleted DEREG (depletion of regulatory T cells) mice, we demonstrated that part of the protumorigenic effect of Tregs was dependent on their expression of CD73. CD73-deficient mice were also protected against pulmonary metastasis of B16F10 melanoma cells after intravenous injection. Unexpectedly, we found that the prometastatic effect of host-derived CD73 was dependent on CD73 expression on nonhematopoietic cells. CD73 expression on nonhematopoietic cells, most likely endothelial cells, was critical for promoting lung metastasis in a manner independent from immunosuppressive effects. Notably, in vivo blockade of CD73 with a selective inhibitor or anti-CD73 monoclonal antibody significantly reduced tumor growth and metastasis of CD73-negative tumors. Taken together, our findings indicate that CD73 may be targeted at multiple levels to induce anticancer effects including at the level of tumor cells, Tregs, and nonhematopoietic cells.
authors.affiliation: Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. john.stagg.chum@ssss.gouv.qc.ca
authors.forename: John
authors.initials: J
authors.lastname: Stagg
authors.forename: Upulie
authors.initials: U
authors.lastname: Divisekera
authors.forename: Helene
authors.initials: H
authors.lastname: Duret
authors.forename: Tim
authors.initials: T
authors.lastname: Sparwasser
authors.forename: Michele W L
authors.initials: MW
authors.lastname: Teng
authors.forename: Phillip K
authors.initials: PK
authors.lastname: Darcy
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Smyth
mesh_terms: D015720:5'-Nucleotidase / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000172:deficiency* / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D048708:Cell Growth Processes / Q000276:immunology; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology* / Q000556:secondary*; D008223:Lymphoma / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008546:Melanoma, Experimental / Q000276:immunology / Q000473:pathology / Q000556:secondary / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology* / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D015720:5'-Nucleotidase